{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:51:45Z","timestamp":1789545105691,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-006052"],"award-info":[{"award-number":["INV-006052"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220211"],"award-info":[{"award-number":["220211"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.pt.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T08:30:41Z","timestamp":1654590641000},"page":"673-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacokinetic considerations in seasonal malaria chemoprevention"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3839-9777","authenticated-orcid":false,"given":"Palang","family":"Chotsiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-1978","authenticated-orcid":false,"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-4030","authenticated-orcid":false,"given":"Joel","family":"Tarning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2022.05.003_bb0005","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ncomms1879","article-title":"Estimating the potential public health impact of seasonal malaria chemoprevention in African children","volume":"3","author":"Cairns","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2022.05.003_bb0010","article-title":"Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2022.05.003_bb0015","author":"World Health Organization"},{"key":"10.1016\/j.pt.2022.05.003_bb0020","series-title":"Seasonal Malaria Chemoprevention with Sulfadoxine-Pyrimethamine Plus Amodiaquine in Children: a Field Guide","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.pt.2022.05.003_bb0025","series-title":"World Malaria Report 2021","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.pt.2022.05.003_bb0030","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(20)32227-3","article-title":"Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study","volume":"396","author":"ACCESS-SMC Partnership","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2022.05.003_bb0035","series-title":"Guidelines for the Treatment of Malaria","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.pt.2022.05.003_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-3156.2006.01784.x","article-title":"How much fat is necessary to optimize lumefantrine oral bioavailability?","volume":"12","author":"Ashley","year":"2007","journal-title":"Tropical Med. Int. Health"},{"key":"10.1016\/j.pt.2022.05.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002579","article-title":"Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis","volume":"15","author":"Kloprogge","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2022.05.003_bb0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2011.254","article-title":"Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria","volume":"91","author":"Tarning","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2022.05.003_bb0055","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41467-019-08297-9","article-title":"Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children","volume":"10","author":"Chotsiri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2022.05.003_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pt.2022.05.003_bb0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.pt.2022.05.003_bb0070","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1473-3099(16)30269-9","article-title":"Does antimalarial mass drug administration increase or decrease the risk of resistance?","volume":"17","author":"White","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2022.05.003_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2022.05.003_bb0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.01700-12","article-title":"Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania","volume":"57","author":"Staehli Hodel","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0085","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1128\/AAC.01075-10","article-title":"Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy","volume":"55","author":"Salman","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01370-17","article-title":"Population pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria","volume":"62","author":"de Kock","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0095","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1128\/AAC.01242-12","article-title":"Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy","volume":"56","author":"Tarning","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/cpt.1707","article-title":"Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in African children","volume":"107","author":"Ding","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2022.05.003_bb0105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.01161-09","article-title":"Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children","volume":"54","author":"Cairns","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0110","article-title":"Safety of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine when delivered to children under 10 years of age by district health services in Senegal: results from a stepped-wedge cluster randomized trial","volume":"11","author":"Ndiaye","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2022.05.003_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003766","article-title":"The cardiovascular effects of amodiaquine and structurally related antimalarials: an individual patient data meta-analysis","volume":"18","author":"Chan","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2022.05.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02193-17","article-title":"Population pharmacokinetics of the antimalarial amodiaquine: a pooled analysis to optimize dosing","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210789","article-title":"Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial","volume":"14","author":"Sottas","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2022.05.003_bb0130","author":"OPT\u2013SMC"},{"key":"10.1016\/j.pt.2022.05.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005311","article-title":"Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention","volume":"6","author":"Bergstrand","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2022.05.003_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002212","article-title":"Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis","volume":"14","author":"Hoglund","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2022.05.003_bb0145","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.04923-14","article-title":"Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso","volume":"59","author":"Zongo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0150","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijantimicag.2016.11.017","article-title":"Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine\/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial","volume":"49","author":"Matangila","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.pt.2022.05.003_bb0155","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","article-title":"Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study","volume":"21","author":"Uwimana","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2022.05.003_bb0160","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1128\/AAC.05877-11","article-title":"Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria","volume":"56","author":"Lwin","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0165","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/cid\/ciu150","article-title":"Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial","volume":"58","author":"Nankabirwa","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2022.05.003_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02491-16","article-title":"Prediction of improved antimalarial chemoprevention with weekly dosing of dihydroartemisinin-piperaquine","volume":"61","author":"Permala","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007164","article-title":"Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children","volume":"4","author":"Cisse","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2022.05.003_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013438","article-title":"Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren","volume":"5","author":"Nankabirwa","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2022.05.003_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011759","article-title":"Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children","volume":"5","author":"Clark","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pt.2022.05.003_bb0190","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1086\/375419","article-title":"Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi","volume":"187","author":"Kublin","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pt.2022.05.003_bb0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12936-017-1841-9","article-title":"Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine","volume":"16","author":"Greenwood","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2022.05.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002762","article-title":"Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: A cluster-randomised trial","volume":"16","author":"Ndiaye","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.pt.2022.05.003_bb0205","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02476-17","article-title":"Characterizing blood-stage antimalarial drug mic values in vivo using reinfection patterns","volume":"62","author":"Watson","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2014.29","article-title":"Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand","volume":"3","author":"Tarning","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.pt.2022.05.003_bb0215","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/cpt.1531","article-title":"Severe acute malnutrition results in lower lumefantrine exposure in children treated with artemether-lumefantrine for uncomplicated malaria","volume":"106","author":"Chotsiri","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pt.2022.05.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00479-17","article-title":"Controlled human malaria infection: applications, advances, and challenges","volume":"86","author":"Stanisic","year":"2018","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2022.05.003_bb0225","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01583-20","article-title":"Semimechanistic pharmacokinetic and pharmacodynamic modeling of piperaquine in a volunteer infection study with Plasmodium falciparum blood-stage malaria","volume":"65","author":"Wattanakul","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2022.05.003_bb0230","series-title":"Malaria Policy Advisory Group (MPAG) Meeting, October 2021","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.pt.2022.05.003_bb0235","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49058","article-title":"Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection","volume":"8","author":"Cao","year":"2019","journal-title":"eLife"}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492222001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492222001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:39:41Z","timestamp":1761464381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492222001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1471492222001064"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2022.05.003","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic considerations in seasonal malaria chemoprevention","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}